Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Some experimental models may observe: Temporary recovery-related response variability Changes in tissue-related sensitivity Adaptation-related physiological variability Individual differences in regenerative-response patterns Administration & Handling Considerations Improper storage, reconstitution, or administration techniques may increase the risk of: Administration-site irritation Local inflammation Reduced peptide stability or effectiveness Additional Research Notes Higher-frequency protocols may increase the likelihood of local irritation or sensitivity-related observations
approval in 2005
J Biol Chem 274 : 2596325966
Injection site reactions, flushing, and transient hyperglycemia are reported but rare
These LL-37/DNA complexes are potent activators of plasmacytoid dendritic cells, triggering massive production of type I interferons, the same cytokines that drive the "interferon signature" characteristic of active lupus
